Clinical Trial Update: Rasburicase and Allopurinol in Treating Patients With Hematologic Malignancies [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating rasburicase and allopurinol in adults with hematologic malignancies; the study was terminated with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Blastic-phase Chronic Myeloid Leukemia
• Burkitt Lymphoma
• Myelodysplastic Syndromes

Drugs mentioned

• Allopurinol (Allopurinol)
• Rasburicase (rasburicase)

Snippet

Sponsor: Roswell Park Cancer Institute | Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q) | Phase 2 | Status: TERMINATED | Results posted: 2017-12-08